evaluation of hepatoprotective effect of silymarin among under treatment tuberculosis patients: a randomized clinical trial

Authors

majid marjani clinical tuberculosis and epidemiology research center

parvaneh baghaei clinical tuberculosis and epidemiology research center

mehdi kazempour dizaji mycobacteriology research center

pegah gorji bayani clinical tuberculosis and epidemiology research center

abstract

hepatic toxicity is the most serious adverse effect of anti tuberculosis drugs. this study was performed to evaluate efficacy of silymarin as a hepatoprotective herbal agent. in a randomized double blind clinical trial 70 new cases of pulmonary tuberculosis were divided into two groups. the intervention group was assigned to receive silymarin and the control group received placebo. tuberculosis was treated by classic regimen consisting isoniazid, rifampin, pyrazinamide and ethambutol. no statistically significant difference was found between the two groups concerning the frequency of drug induced liver injury or mild elevation of liver enzymes. silymarin was safe without any major side effect. our results showed no significant hepatoprotective effect of silymarin among patients on tuberculosis treatment.trial registration: anzctr registration id: actrn12610000621011.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

Evaluation of Hepatoprotective Effect of Silymarin Among Under Treatment Tuberculosis Patients: A Randomized Clinical Trial

Hepatic toxicity is the most serious adverse effect of anti tuberculosis drugs. This study was performed to evaluate efficacy of silymarin as a hepatoprotective herbal agent. In a randomized double blind clinical trial 70 new cases of pulmonary tuberculosis were divided into two groups. The intervention group was assigned to receive silymarin and the control group received placebo. Tuberculosis...

full text

Evaluation of Hepatoprotective Effect of Silymarin Among Under Treatment Tuberculosis Patients: A Randomized Clinical Trial

Hepatic toxicity is the most serious adverse effect of anti tuberculosis drugs. This study was performed to evaluate efficacy of silymarin as a hepatoprotective herbal agent. In a randomized double blind clinical trial 70 new cases of pulmonary tuberculosis were divided into two groups. The intervention group was assigned to receive silymarin and the control group received placebo. Tuberculosis...

full text

Evaluation of Hepatoprotective Effect of Silymarin Among Under Treatment Tuberculosis Patients: A Randomized Clinical Trial

Hepatic toxicity is the most serious adverse effect of anti-tuberculosis drugs. This study was performed to evaluate the efficacy of silymarin as a hepatoprotective herbal agent. In a randomized double blind clinical trial, 70 new cases of pulmonary tuberculosis were divided into two groups. The intervention group was assigned to receive silymarin and the control group received placebo. Tubercu...

full text

Silymarin in treatment of non-alcoholic steatohepatitis: A randomized clinical trial

Abstract Background: No pharmacologic agents have been approved for the treatment of non-alcoholic steatohepatitis (NASH) that is common in our region. The present study was designed to evaluate the efficacy of silymarin, a known herbal drug, in the treatment of NASH. Methods: This clinical-trial study was conducted on 64 patients with NASH who were randomly divided as case group (33) and con...

full text

Effect of Statin Treatment on COVID-19 Patients’ Outcomes: A Randomized Double-blind Controlled Clinical Trial

Background: Statins may be protective against viral infection and have been suggested for the treatment of coronavirus disease 2019 (COVID-19).  Objective: In this study, we aimed to evaluate the effect of atorvastatin on COVID-19 patients. Methods: Our study is a randomized double-blind controlled clinical trial that constitutes a population of COVID-19 patients admitted to Bu-Ali Sina Hospi...

full text

Deferoxamine Protective Effect in Preventing Nephrotoxicity in Children Under Treatment with Doxorubicin: A Randomized Clinical Trial

Background: Nephrotoxicity secondary to doxorubicin (DOX) may be associated with high morbidity and mortality rates. We aimed to assess the efficacy of Deferoxamine (DFO) in preventing DOX-induced nephrotoxicity in pediatric malignancy. Methods: This Parallel-group randomized clinical trial was done on 62 children aged 2-18 years who had new onset malignancy treated with DOX. They were randoml...

full text

My Resources

Save resource for easier access later


Journal title:
iranian journal of pharmaceutical research

جلد ۱۵، شماره ۱، صفحات ۲۴۷-۲۵۲

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023